The following documents are available online:

Alexander JH, Dyke CK, Yang H, et al. Initial experience with factor Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI pilot. Study Participants.

Califf RM, Pieper KS, Lee KL, et al. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the GUSTO-I trial. Circulation 2000;101:2231-8. Statistical Appendix.

Chang W-C, Pieper KS, Boersma E, et al. Dynamic prognostication in non-ST elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. Baseline characteristics; Methodological issues; Technical Appendix 2.

Jollis JG, Landolfo CL, Kisslo J, et al. Fenfluramine and phentermine and cardiovascular findings: the effect of treatment duration on prevalence of valve abnormalities. Circulation 2000;101 2071-7. Appendix 1; Manuscript Tables.

Newby LK, Storrow AB, Gibler WB, et al. Bedside multimarker testing for risk stratification in the CHECKMATE Study, response to Letter to the Editor. Circulation 2001. Table

The PARAGON-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation 2002;105:316-21. Participants.

The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation. N Engl J Med 1998;339:436-43. Appendix.

Rosen AB, Fowler VG Jr, Corey GR, et al. Cost-effectiveness of transesophageal echocardiography in determining the duration of therapy for patients with intravascular catheter-associated Staphylococcus aureus bacteremia. Ann Intern Med 1999;130:810-20. Technical Report.

The 2nd SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 2001;103:1727-33. Appendix.

Stamler JS, Taber RL, Califf RM. A balanced approach to the translation of academic discovery into societal benefit. Am J Med 2003;115:596-9. Appendix.

Tardiff BE, Jennings L, Harrington RA, et al. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from the PURSUIT trial. Circulation 2001;104:399-405. Appendices.